Guang Sheng Tang-Neraprazole initiated a Phase I clinical trial in China for liver injury and chronic hepatitis B.
April 24, 2026
Source: drugdu
51
On April 23, 2026, Guang Sheng Tang initiated a Phase I clinical trial in China for nerecvir (an HBcAg inhibitor) for the indication of liver injury and chronic hepatitis B. The trial (CTR20261605), titled "Pharmacokinetics and Safety Study of GST-HG141 Tablets in Participants with Impaired and Normal Liver Function," plans to enroll 24 subjects.
The investigational drug in this clinical trial is Neratrovir.
The primary endpoints include the following pharmacokinetic parameters: Cmax (maximum plasma concentration), Tmax (time to peak concentration), t1 /2 (half-life), AUC0 -t (area under the curve from dosing to the last detection time), AUC0 -∞ (area under the curve from dosing to infinity), CL/F (apparent clearance), Vz/F (apparent volume of distribution), and plasma protein binding rate.
https://bydrug.pharmcube.com/news/detail/794753dd6168e510cf7df98863df6eea
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- the global setbacks of FIC April 24, 2026
- Yingpai Pharmaceutical is about to go public. April 24, 2026
- Breaking News! The world’s leading medical device company completes a major acquisition. April 24, 2026
- Maiwei Biotech adds another potential drug April 24, 2026
- The Hidden Champion in the Chronic Disease Market April 24, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
